The nebraska experience

Margaret Anne Kessinger

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Autologous peripheral stem cell transplantation was initiated at the University of Nebraska Medical Center to provide hematopoietic rescue for patients who were candidates for high‐dose therapy but had marrows that were unfit for autografting. From 1984 until 1991, the cells were collected during steady state without mobilization. These cells restored hematopoietic function at a rate similar to that of autologous marrow in patients not treated with total body irradiation. Patients who received total body irradiation experienced slower hematopoietic recovery. When growth factors became generally available in the United States in 1991, mobilization with cytokines became standard at Nebraska. In recent years, the function of cells other than hematopoietic progenitors contained in a peripheral stem cell apheresis product has been studied. Detection of tumor cells using cell culture, immunocytochemical and polymerase chain reaction techniques has revealed that such collections are less likely to contain, or contain fewer, tumor cells than autologous bone marrow harvests. More antitumor cytotoxic activity was found in cells in peripheral stem cell collections than in marrow cell collections. The immunocompetent lymphocyte population is larger in peripheral stem cell collection than in marrow harvests, and immunologic recovery after peripheral stem cell transplant has differed compared to recovery following bone marrow transplantation. The future of peripheral stem cell transplantation is likely to include engineering of the graft products specific for the patient and disease being treated. Determining the function of accessory cells in a peripheral stem cell collection will be important to provide the best engineered product for the patient.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalSTEM CELLS
Volume13
Issue number3 S
DOIs
StatePublished - Jan 1 1995

Fingerprint

Bone Marrow
Peripheral Blood Stem Cell Transplantation
Whole-Body Irradiation
Transplants
Blood Component Removal
Autologous Transplantation
Hematopoietic Stem Cells
Bone Marrow Transplantation
Bone Marrow Cells
Neoplasms
Intercellular Signaling Peptides and Proteins
Cell Culture Techniques
Peripheral Blood Stem Cells
Lymphocytes
Cytokines
Polymerase Chain Reaction
Population
Therapeutics

Keywords

  • Autologous transplantation
  • Cytokine mobilization
  • Peripheral stem cell

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

The nebraska experience. / Kessinger, Margaret Anne.

In: STEM CELLS, Vol. 13, No. 3 S, 01.01.1995, p. 23-27.

Research output: Contribution to journalArticle

Kessinger, MA 1995, 'The nebraska experience', STEM CELLS, vol. 13, no. 3 S, pp. 23-27. https://doi.org/10.1002/stem.5530130705
Kessinger, Margaret Anne. / The nebraska experience. In: STEM CELLS. 1995 ; Vol. 13, No. 3 S. pp. 23-27.
@article{b3380ba876a44633b864202ff70226f9,
title = "The nebraska experience",
abstract = "Autologous peripheral stem cell transplantation was initiated at the University of Nebraska Medical Center to provide hematopoietic rescue for patients who were candidates for high‐dose therapy but had marrows that were unfit for autografting. From 1984 until 1991, the cells were collected during steady state without mobilization. These cells restored hematopoietic function at a rate similar to that of autologous marrow in patients not treated with total body irradiation. Patients who received total body irradiation experienced slower hematopoietic recovery. When growth factors became generally available in the United States in 1991, mobilization with cytokines became standard at Nebraska. In recent years, the function of cells other than hematopoietic progenitors contained in a peripheral stem cell apheresis product has been studied. Detection of tumor cells using cell culture, immunocytochemical and polymerase chain reaction techniques has revealed that such collections are less likely to contain, or contain fewer, tumor cells than autologous bone marrow harvests. More antitumor cytotoxic activity was found in cells in peripheral stem cell collections than in marrow cell collections. The immunocompetent lymphocyte population is larger in peripheral stem cell collection than in marrow harvests, and immunologic recovery after peripheral stem cell transplant has differed compared to recovery following bone marrow transplantation. The future of peripheral stem cell transplantation is likely to include engineering of the graft products specific for the patient and disease being treated. Determining the function of accessory cells in a peripheral stem cell collection will be important to provide the best engineered product for the patient.",
keywords = "Autologous transplantation, Cytokine mobilization, Peripheral stem cell",
author = "Kessinger, {Margaret Anne}",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/stem.5530130705",
language = "English (US)",
volume = "13",
pages = "23--27",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "3 S",

}

TY - JOUR

T1 - The nebraska experience

AU - Kessinger, Margaret Anne

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Autologous peripheral stem cell transplantation was initiated at the University of Nebraska Medical Center to provide hematopoietic rescue for patients who were candidates for high‐dose therapy but had marrows that were unfit for autografting. From 1984 until 1991, the cells were collected during steady state without mobilization. These cells restored hematopoietic function at a rate similar to that of autologous marrow in patients not treated with total body irradiation. Patients who received total body irradiation experienced slower hematopoietic recovery. When growth factors became generally available in the United States in 1991, mobilization with cytokines became standard at Nebraska. In recent years, the function of cells other than hematopoietic progenitors contained in a peripheral stem cell apheresis product has been studied. Detection of tumor cells using cell culture, immunocytochemical and polymerase chain reaction techniques has revealed that such collections are less likely to contain, or contain fewer, tumor cells than autologous bone marrow harvests. More antitumor cytotoxic activity was found in cells in peripheral stem cell collections than in marrow cell collections. The immunocompetent lymphocyte population is larger in peripheral stem cell collection than in marrow harvests, and immunologic recovery after peripheral stem cell transplant has differed compared to recovery following bone marrow transplantation. The future of peripheral stem cell transplantation is likely to include engineering of the graft products specific for the patient and disease being treated. Determining the function of accessory cells in a peripheral stem cell collection will be important to provide the best engineered product for the patient.

AB - Autologous peripheral stem cell transplantation was initiated at the University of Nebraska Medical Center to provide hematopoietic rescue for patients who were candidates for high‐dose therapy but had marrows that were unfit for autografting. From 1984 until 1991, the cells were collected during steady state without mobilization. These cells restored hematopoietic function at a rate similar to that of autologous marrow in patients not treated with total body irradiation. Patients who received total body irradiation experienced slower hematopoietic recovery. When growth factors became generally available in the United States in 1991, mobilization with cytokines became standard at Nebraska. In recent years, the function of cells other than hematopoietic progenitors contained in a peripheral stem cell apheresis product has been studied. Detection of tumor cells using cell culture, immunocytochemical and polymerase chain reaction techniques has revealed that such collections are less likely to contain, or contain fewer, tumor cells than autologous bone marrow harvests. More antitumor cytotoxic activity was found in cells in peripheral stem cell collections than in marrow cell collections. The immunocompetent lymphocyte population is larger in peripheral stem cell collection than in marrow harvests, and immunologic recovery after peripheral stem cell transplant has differed compared to recovery following bone marrow transplantation. The future of peripheral stem cell transplantation is likely to include engineering of the graft products specific for the patient and disease being treated. Determining the function of accessory cells in a peripheral stem cell collection will be important to provide the best engineered product for the patient.

KW - Autologous transplantation

KW - Cytokine mobilization

KW - Peripheral stem cell

UR - http://www.scopus.com/inward/record.url?scp=0028819915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028819915&partnerID=8YFLogxK

U2 - 10.1002/stem.5530130705

DO - 10.1002/stem.5530130705

M3 - Article

VL - 13

SP - 23

EP - 27

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 3 S

ER -